CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

Phase 1CG-0416Positive

AI Analysis

Summary

CureGene announced the first participant dose in its Phase I trial of CG-0416, a novel oral liver-targeting THR-β agonist, with subject enrollment progressing smoothly.

Clinical Trial Data

Phase

Phase 1

Patients

Outcome Details

First participant dosed in Phase I trial

Importance:5/10

Sentiment:

0.50

Phase 1 initiationoral drugliver-targetingTHR-beta agonistAustralia

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on August 21, 2026 12:08 PM

Read Original